Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1
Per Edlund(Gävle Hospital), Carl Blomqvist(University of Helsinki), Karsten Bjerre(Danish Breast Cancer Cooperative Group), Henrik Lindman(Uppsala University), Erik Jakobsen(Aarhus University Hospital), Jonas Bergh(Karolinska Institutet), Michael Andersson(University of Copenhagen), Susanne Möller(Danish Breast Cancer Cooperative Group), Nils‐Olof Bengtsson, Stig B. Holmberg(Sahlgrenska University Hospital), Henning T. Mouridsen(Danish Breast Cancer Cooperative Group), Johan Ahlgren(Gävle Hospital)
Cited by 11
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k